|Articles|July 1, 2004

CONTROL, SURVIVAL IMPROVE

ImClone Systems Inc. and Bristol-Myers Squibb Co. report that the combination of Erbitux (cetuximab) injection and high-dose radiation yielded locoregional control and improved survival rate for patients with locally advanced squamous cell carcinoma of the head and neck.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME